ÎåÐÇÌåÓýÖ±²¥ to Present at Upcoming Virtual Healthcare Conferences

REDWOOD CITY, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- ÎåÐÇÌåÓýÖ±²¥ (Nasdaq:CDXS), a leading enzyme engineering company, today announced that management will present at three upcoming virtual investment conferences.

  • The SVB Leerink 10th Annual Global Healthcare Conference – February 26, 2021 at 1:40 p.m. ET
  • The Cowen 41st Annual Health Care Conference – March 4, 2021 at 12:50 p.m. ET, corporate fireside chat; and 2:50 p.m. ET, Synthetic Biology Company CEO Panel
  • The H.C. Wainwright & Co. Global Life Sciences Conference – March 9-10, 2021, on demand

Live webcasts of the SVB Leerink and Cowen conferences presentations will be available in the Investor Relations section of the Company’s website, . Replays of the webcasts will be archived for 30 days following their respective presentation dates.

About ÎåÐÇÌåÓýÖ±²¥

ÎåÐÇÌåÓýÖ±²¥ is a leading enzyme engineering company that applies its proprietary CodeEvolver® technology to develop products for a variety of applications, including as biocatalysts for the commercial manufacture of pharmaceuticals, fine chemicals and industrial enzymes, and enzymes as biotherapeutics and for use in molecular diagnostics. ÎåÐÇÌåÓýÖ±²¥â€™ proven technology enables improvements in protein performance, meeting customer needs for rapid, cost-effective and sustainable manufacturing in multiple commercial-scale implementations of biocatalytic processes.

Forward-Looking Statements

To the extent that statements contained in this press release are not descriptions of historical facts regarding ÎåÐÇÌåÓýÖ±²¥, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve substantial risks and uncertainties that could cause ÎåÐÇÌåÓýÖ±²¥â€™ future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. ÎåÐÇÌåÓýÖ±²¥ undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ÎåÐÇÌåÓýÖ±²¥â€™ business in general, please refer to ÎåÐÇÌåÓýÖ±²¥â€™ prospectus supplement to be filed with the SEC, including the documents incorporated by reference therein, which include ÎåÐÇÌåÓýÖ±²¥â€™ Annual Report on Form 10-K filed with the SEC on February 28, 2020, ÎåÐÇÌåÓýÖ±²¥â€™ Quarterly Report on Form 10-Q filed with the SEC on November 6, 2020, and ÎåÐÇÌåÓýÖ±²¥â€™ other periodic reports filed with the SEC.

Investor Relations Contact:
Argot Partners
Stephanie Marks/Natallia Clancy
(212) 600-1902
ÎåÐÇÌåÓýÖ±²¥@argotpartners.com


Source: ÎåÐÇÌåÓýÖ±²¥